Tempus AI is a growth stock that is down 31% from all-time highs. Here's why TEM AI stock could be a part of your TFSA portfolio right now.

TEM stock rallies 7.3% after the FDA clears its second cardiology AI tool, witnessing a 48% surge in just three months.

Tempus AI TEM expects full-year 2025 revenues of $1.25 billion (up from the previous $1.24 billion guidance), which represents approximately 80% annual growth. The company also expects adjusted EBITDA ...

Tempus AI Inc (NASDAQ: TEM) came ... Spruce Point cited several reasons, including account irregularities and eroding ties with key clients like AstraZeneca, for its bet against the Nasdaq listed ...

Tempus Announces Expansion of Collaboration with AstraZeneca to Leverage Tempus Next to Support Guideline-directed Biomarker Testing in NSCLC. June 01, 2024 09:30 AM Eastern Daylight Time.

Tempus, a leader in artificial intelligence and precision medicine, today announced a multi-year, strategic collaboration with AstraZeneca in which the two companies will work together to gather ...

Shares of Tempus AI (NASDAQ: TEM) were skyrocketing 16.5% higher as of 10:39 a.m. ET on Wednesday. The big gain came after the healthcare artificial intelligence (AI) company announced a multiyear ...

Tempus AI said it will work with AstraZeneca and Pathos AI to build a multimodal foundation model in oncology that can gather biological and clinical insights, discover novel drug targets and ...

CHICAGO - Tempus AI, Inc. (NASDAQ: TEM), a leader in applying artificial intelligence (AI) to healthcare, has announced strategic collaborations with pharmaceutical giant AstraZeneca (LSE/STO/Nasdaq: ...

Tempus AI Stock Sees +21% Gain in 3 Days: Is It a Buy After AZN Deal? Tempus AI has skyrocketed 21% in the last three days, fueled by news of a $200 million partnership with AstraZeneca and Pathos AI.

CHICAGO--(BUSINESS WIRE)--Tempus, a leader in artificial intelligence and precision medicine, today announces an expansion of its collaboration with AstraZeneca, which leverages Tempus Next to arm ...